Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Endo Pharmaceuticals Stories

2013-12-16 08:25:33

MALVERN, Pa., Dec. 16, 2013 /PRNewswire/ -- -- Accretive transaction furthers Endo's transformation into leading specialty healthcare company -- Builds on Endo's leadership in pain management through addition of ZECUITY(®) (sumatriptan iontophoretic transdermal system), the first and only FDA approved patch to treat migraine -- Proven Endo branded pharmaceuticals commercial team to execute ZECUITY launch, expected in first half 2014 Endo...

2013-12-11 00:20:47

MALVERN, Pa., Dec. 10, 2013 /PRNewswire/ -- Endo Health Solutions (NASDAQ: ENDP) today announced that Arthur J. Higgins has been appointed to its Board of Directors, effective immediately. Endo also announced that Joseph C. Scodari, 60, will retire as a director, effective December 31, 2013. Recognized for his strategic capabilities, Mr. Higgins has over 30 years of domestic and international pharmaceutical industry experience. He is currently a Senior Advisor to Blackstone...

2013-12-05 23:04:28

Reportbuyer.com just published a new market research report: Drug Delivery Partnering Terms and Agreements. London (PRWEB) December 05, 2013 The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals....

2013-11-27 20:22:20

MALVERN, Pa., Nov. 27, 2013 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) ("Endo") today announced that, as reported by the tabulation agent, the requisite holders of its senior notes listed below (collectively the "Notes") had consented to the proposed amendments to the indentures governing the Notes (the "Proposed Amendments"), upon the terms and subject to the conditions set forth in the Consent Solicitation Statement, dated November 19, 2013 (the "Statement")....

2013-11-20 00:21:01

MALVERN, Pa., Nov. 19, 2013 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) ("Endo") today announced that it has commenced consent solicitations with respect to proposed amendments to the indentures governing its senior notes listed below (collectively the "Notes"), upon the terms and subject to the conditions set forth in the Consent Solicitation Statement, dated November 19, 2013 (the "Statement"). Series of Notes CUSIP Outstanding Principal Amount...

2013-11-11 16:23:43

MALVERN, Pa., Nov. 11, 2013 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced that Rajiv De Silva, President and CEO, will present a corporate overview at the 2013 Credit Suisse Healthcare Conference on Tuesday, November 12, 2013 at 2:30 p.m. Mountain Standard Time. A live webcast and audio archive of the presentation will be available on the company's website at www.endo.com. Click on Investor Relations, and then the link to the Event and Presentation....

2013-11-05 08:33:20

MALVERN, Pa. and MONTREAL, Nov. 5, 2013 /PRNewswire/ -- -- Accelerates Endo's transformation to leading global specialty healthcare company and creates platform for future growth -- Paladin Labs' proven Canadian franchise, robust near-term pipeline and emerging market business complement Endo's U.S. strengths -- Combined company expects to grow presence in North America and internationally -- Stock and cash transaction values Paladin Labs at...

2013-10-29 12:28:55

MALVERN, Pa., Oct. 29, 2013 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) will announce its third quarter 2013 financial results before the open of the U.S. financial markets on November 7, 2013 and members of its senior management team will host a conference call and webcast at 8:00 a.m. ET that day to discuss these results. Investors and other interested parties may call 866-515-2911 (domestic) or 617-399-5125 (international) and enter passcode 70911744. Please dial in...

2013-09-12 16:27:43

PARSIPPANY, N.J., Sept. 12, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that it has launched Oxymorphone Hydrochloride Extended-release Tablets, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg. Actavis' ANDA product is the generic equivalent to the previously marketed formulation of Endo Health Solutions' Opana(® )ER, which was voluntarily withdrawn from sale in 2012. Actavis previously received approval for, and is currently marketing, Oxymorphone Hydrochloride...

2013-09-09 08:27:41

MALVERN, Pa., Sept. 9, 2013 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP), a U.S. based specialty healthcare company, announced today that it had appointed Suketu "Suky" Upadhyay as executive vice president and chief financial officer of Endo, effective September 23, 2013. "We are delighted to have Suky join the Endo team at this pivotal time," said Rajiv De Silva, president and chief executive officer of Endo. "He brings significant healthcare industry experience and...